Urology Times staff

Antegrade mitomycin gel instillation was done through a percutaneous nephrostomy tube.

Philippe Spiess, MD, Moffitt Cancer Center, discusses the latest developments in the evolving treatment paradigm for patients with penile cancer.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

Based on previously reported CheckMate-274 data, the FDA approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma.

"The ProVee System has the potential to be an effective treatment for BPH that can be safely and reliably performed in the office setting," according to Steve Kaplan, MD.

“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.

"One of the main goals of our interactions with patients is to increase adherence," said Amy Pfeifer, PharmD, BCPS, CSP.

"We believe this novel treatment strategy will improve the lives of many prostate cancer patients,” said lead study investigator Behfar Ehdaie, MD.

Joshua J. Meeks, MD, PhD, recaps several presentations on bladder cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.

“We're doing probably one of the highest volume of HoLEP cases…in the United States,” says Nicole L. Miller, MD, FACS.

Ashley E. Ross, MD, PhD, recaps several presentations on prostate cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.

Philippe Spiess, MD, MS, FACS, recaps several presentations from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.

The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to frontline abiraterone acetate significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

In this interview, Justin Dubin, MD, discusses the development of treatments for male infertility.

“When you're talking about ‘impact,’ I don't think it gets any bigger than treating male infertility, because you're surgically treating the man, of course, but you're really treating the couple as a whole, and you're helping potentially create a new life,” says Justin Dubin, MD.

Guru P. Sonpavde, MD, discusses the 2022 ASCO Annual Meeting abstract, “Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.”

Phillip Kuo, MD, PhD, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.

“I think that there's certainly recognition that HoLEP is a procedure that can be self-taught and learned. But I think the learning curve is significantly shortened if you're mentored and certainly if you're fellowship trained,” says Nicole L. Miller, MD, FACS.

“Several years ago, we eliminated the high stakes component of our exam and made it into more of an educational process,” says David Joseph, MD.

In their study, Joshua Halpern, MD, and co-investigators examined the link between low testosterone and frailty in veterans undergoing cancer surgery.

Sumanta K. Pal, MD, highlights next steps now that the combination of cabozantinib and atezolizumab showed promising clinical activity in bladder cancer in the phase 1b COSMIC-021 trial.

Robert E. Brannigan, MD, discusses which men with infertility issues should receive genetic testing.

“We showed in this controlled study that the mindfulness meditation decreases anxiety level and has a positive effect on pain and also on patient satisfaction,” says Andrea Staack, MD, PhD.

In this installment, Howard B. Goldman, MD, FACS, discusses the development of multichannel urodynamics testing.

Barrigel, which is made from Non-Animal Stabilized Hyaluronic Acid (NASHA), is used to separate and increase the distance between the anterior rectal wall and the prostate when the patient is receiving radiotherapy.

“What made [multichannel urodynamics] so important is you're able to diagnose things much better; you're able to have a much better understanding of what's actually going on,” says Howard B. Goldman, MD, FACS.

Guru P. Sonpavde, MD, highlights long-term data from the phase 3 EV-301 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

Pal highlights results from the phase 1b COSMIC-021 trial in which cabozantinib plus atezolizumab showed promising clinical activity in patients with urothelial carcinoma.

The ENZAMET study explored enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.